Monoclonal antibodies to chikungunya virus

Two human monoclonal antibodies that potently neutralize Chikungunya virus both in vitro and in vivo.
Chikungunya is an emerging viral disease of public health importance. While about majority of the individuals recover from primary illness, many come down with persistent debilitating arthralgia resulting in prolonged morbidity. Currently, there is no vaccine, anti-viral treatment strategies or optimal diagnostics towards the infection. Therefore, availability of human monoclonals towards Chikungunya virus infections will greatly improve accessibility to anti-viral strategies and complement other treatment efforts.

There is no current option of a universal monoclonal antibody based therapeutic for ChikV.

o The Chikungunya specific human monoclonals have been made from single cell sorting Chikungunya virus specific memory B cells from Chikungunya immune individuals in India – no other lab in the world has utilized these samples for this purpose.
o These CHIKV specific human monoclonals bind to the whole Chikv virus have unique antibody sequences have not been reported elsewhere. The heavy and light chain sequences of both the Chikv specific monoclonals is attached to this application.
o The IC-50 of clone 96F C12 is 0.002ug/ml and A41 A9 clone is 0.086ug/ml.

CHIKV neutralizing human MAbs generated in India opens indigenous opportunities for bench to bedside translational applications including GMP production, preclinical and clinical evaluation to fast track therapeutic clinical interventions to Chikungunya associated acute arthritis.

Technology available for commercialization.

Yes, the invention requires a GMP grade facility to grow large batches of human monoclonal antibodies. Also, the monoclonals can be sub-cloned into stable expression vectors for further up scaling capacity. Estimated cost is not known.

Indian patent filed on 19-05-2023, 202311035194